Cargando…

Bardoxolone methyl: drug development for diabetic kidney disease

Bardoxolone methyl activates the Keap1/Nrf2 system that plays an important role in defense responses against oxidative stress. Importantly, bardoxolone methyl has demonstrated increases in estimated glomerular filtration rate (eGFR) in patients with diabetic kidney disease (DKD) in clinical studies....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanda, Hironori, Yamawaki, Kengo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497696/ https://www.ncbi.nlm.nih.gov/pubmed/32594372 http://dx.doi.org/10.1007/s10157-020-01917-5

Ejemplares similares

Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
por: Rojas-Rivera, Jorge, et al.
Publicado: (2012)

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl
por: McCullough, Peter A, et al.
Publicado: (2012)

Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function
por: Nagasu, Hajime, et al.
Publicado: (2019)

Anticholestatic Effect of Bardoxolone Methyl on Hepatic Ischemia-reperfusion Injury in Rats
por: Kim, Joohyun, et al.
Publicado: (2020)

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
por: Wang, Yan-Yang, et al.
Publicado: (2014)

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease
por: Sun, Qi, et al.
Publicado: (2021)

Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD
por: Lewis, James H., et al.
Publicado: (2020)

Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice
por: Dinh, Chi H. L., et al.
Publicado: (2015)

Bardoxolone methyl ameliorates osteoarthritis by inhibiting osteoclastogenesis and protecting the extracellular matrix against degradation
por: Yang, Ruijia, et al.
Publicado: (2023)

Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro
por: Chi, Ying Lin, et al.
Publicado: (2023)

In vitro study on effect of bardoxolone methyl on cisplatin-induced cellular senescence in human proximal tubular cells
por: Kurosaki, Yoshifumi, et al.
Publicado: (2022)

Bardoxolone conjugation enables targeted protein degradation of BRD4
por: Tong, Bingqi, et al.
Publicado: (2020)

Repeated glucose spikes and insulin resistance synergistically deteriorate endothelial function and bardoxolone methyl ameliorates endothelial dysfunction
por: Ogiso, Kazuma, et al.
Publicado: (2022)

Bardoxolone Methyl Ameliorates Myocardial Ischemia/Reperfusion Injury by Activating the Nrf2/HO-1 Signaling Pathway
por: Huang, Anwu, et al.
Publicado: (2023)

Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells
por: Wang, Yan-Yang, et al.
Publicado: (2015)

Bardoxolone-Methyl Prevents Oxidative Stress-Mediated Apoptosis and Extracellular Matrix Degradation in vitro and Alleviates Osteoarthritis in vivo
por: Pang, Zhiying, et al.
Publicado: (2021)

Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells
por: Hermann, Cornelius, et al.
Publicado: (2021)

The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy
por: Chien, Jia-Ying, et al.
Publicado: (2021)

Bardoxolone Methyl Ameliorates Compression-Induced Oxidative Stress Damage of Nucleus Pulposus Cells and Intervertebral Disc Degeneration Ex Vivo
por: Tian, Yueyang, et al.
Publicado: (2022)

46 Bardoxolone-methyl Microparticles Ameliorate Immune Dysfunction Following Burn and Inhalation Injury Through the NRF2/KEAP1 Axis
por: Seim, Roland F, et al.
Publicado: (2022)

Bardoxolone Methyl Prevents Fat Deposition and Inflammation in Brown Adipose Tissue and Enhances Sympathetic Activity in Mice Fed a High-Fat Diet
por: Dinh, Chi H. L., et al.
Publicado: (2015)

Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium
por: Szczesny-Malysiak, Ewa, et al.
Publicado: (2020)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

Analgesic Effects of Fisetin, Peimine, Astaxanthin, Artemisinin, Bardoxolone Methyl and 740 Y-P and Their Influence on Opioid Analgesia in a Mouse Model of Neuropathic Pain
por: Ciapała, Katarzyna, et al.
Publicado: (2023)

Keap1-Nrf2 signaling activation by Bardoxolone-methyl ameliorates high glucose-induced oxidative injury in human umbilical vein endothelial cells
por: Yang, Jing-Lei, et al.
Publicado: (2020)

Renoprotection and the Bardoxolone Methyl Story – Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents
por: Onuigbo, Macaulay
Publicado: (2013)

A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)
por: Gatbonton-Schwager, Tonibelle, et al.
Publicado: (2023)

Nonproteinuric diabetic kidney disease
por: Yamanouchi, Masayuki, et al.
Publicado: (2020)

Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me; bardoxolone methyl) on radiation-induced lung inflammation and fibrosis in mice
por: Wang, Yan-Yang, et al.
Publicado: (2015)

Mitochondria-targeted drugs for diabetic kidney disease
por: Mima, Akira
Publicado: (2022)

Clinico-pathological features of kidney disease in diabetic cases
por: Furuichi, Kengo, et al.
Publicado: (2018)

Protein Methylation in Diabetic Kidney Disease
por: Cheng, Ye, et al.
Publicado: (2022)

Development of an Experimental Model for Analyzing Drug Resistance in Colorectal Cancer
por: Elbadawy, Mohamed, et al.
Publicado: (2018)

DNA methylation markers for kidney function and progression of diabetic kidney disease
por: Li, Kelly Yichen, et al.
Publicado: (2023)

DNA Methylation Dysfunction in Chronic Kidney Disease
por: Ingrosso, Diego, et al.
Publicado: (2020)

The Role of Lifestyle Intervention, in Addition to Drugs, for Diabetic Kidney Disease with Sarcopenic Obesity
por: Chen, Shu-Hua, et al.
Publicado: (2022)

Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
por: Kim, Hyo Jin, et al.
Publicado: (2022)

Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
por: Bais, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sqr3l4s7r0tm4uoh9cud4c313b